Pacylex Pharmaceuticals Discusses its Broad-Spectrum Anti-Cancer Drug Zelenirstat at 2024 BIO International Convention
Edmonton, Alberta, Canada May 15, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors as targeted therapies for the treatment of hematologic cancers and solid tumors. Today Pacylex announced that it will be attending the Biotechnology Innovation Organization (BIO) International Convention taking place June 3-6, 2024, at the San Diego